For research use only. Not for therapeutic Use.
Ifinatamab（Cat No.:I042225）is a monoclonal antibody designed to target the glycoprotein PD-1 (programmed cell death protein 1) receptor, which plays a role in immune checkpoint regulation. By blocking PD-1, Ifinatamab enhances the immune system’s ability to recognize and attack cancer cells, overcoming immune evasion mechanisms employed by tumors. It is being studied primarily for the treatment of various cancers, including non-small cell lung cancer and melanoma. Ongoing clinical trials are evaluating Ifinatamab’s safety, efficacy, and potential use in combination with other therapies to improve cancer treatment outcomes.
| Catalog Number | I042225 |
| CAS Number | 2484870-90-6 |
| Purity | ≥95% |
